MANDARIN (S6371)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

October 30, 2026

Conditions
Inoperable Hepatocellular Carcinoma
Interventions
COMBINATION_PRODUCT

TheraSphere™ Yttrium-90 Glass Microspheres

"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"

PROCEDURE

conventional Transarterial Chemoembolization(cTACE)

conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.

Trial Locations (1)

210009

Zhongda Hospital Southeast University, Nanjing

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY